Floatz logo

AZD1775

Unresectable Malignant Solid Neoplasm

National Cancer Institute (NCI)Phase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

58 Active assets in the Unresectable Malignant Solid Neoplasm cohort.

Asset / SponsorPhaseRating
Nivolumab
Fred Hutchinson Cancer Center
Phase 2B
Herzuma
National Cancer Institute (NCI)
Phase 2B
Talzenna
National Cancer Institute (NCI)
Phase 2B
Olaparib
National Cancer Institute (NCI)
Phase 2B
Bet Bromodomain Inhibitor Zen-3694
National Cancer Institute (NCI)
Phase 2B

View all 50 →

Same molecule, other indications

AZD1775 is also rated in:

refractory malignant neoplasmDormant
B
Indicative ·
62 / 100
View asset →
Advanced Malignant Solid NeoplasmDormant
B
Indicative ·
60 / 100
View asset →
exocrine pancreatic carcinomaDormant
B
Indicative ·
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →